DrugRisk Center: Merck Withdraws Cancer Drug As NuvaRing Lawsuits Grow

The Drug Risk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Nuvaring lawsuit
Anyone who suffered blood clots, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact the DrugRisk Resource Center or speak with a lawyer about their legal rights as soon as possible.

Orlando, FL (PRWEB) December 06, 2012

After difficulties earlier this year gaining approval of its cancer treatment ridaforolimus in the United States, drug maker Merck has withdrawn an application for approval of the drug in Europe as well, according to BusinessWeek on November 29, 2012.*

The news for Merck comes as litigation surrounding their popular NuvaRing contraceptive device has grown to 1,028 cases, according to the 2012 Statistical Analysis from the Judicial Panel on MultiDistrict Litigation.** The formal case is known as In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri.

Anyone who suffered blood clots, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact the DrugRisk Resource Center or speak with a lawyer about their legal rights as soon as possible. A NuvaRing lawsuit may be possible to recover damages.

Experts have related vaginal rings like NuvaRing to higher blood clot risks than with traditional birth control pills.

The British Medical Journal published a Danish study on May 10, 2012 linking vaginal rings like NuvaRing to as much as a 90% increased risk of blood clots over oral contraceptives. On June 14, 2012, the New England Journal of Medicine also published a study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots.

So far, the FDA has received more than 1,000 reports of blood clot injury or death in patients using NuvaRing, according to an article in CBS News San Diego on September 21, 2012.
U.S. District Judge Rodney Sippel, who presides over the NuvaRing lawsuits moved to the Missouri federal court from around the country, recently issued an order postponing the start of trials from May 6 to July 8, 2013.**

The delay of trials could give those who have yet to learn their legal rights more time to do so.
The DrugRisk Resource Center urges anyone affected by blood clots, stroke, DVT or pulmonary embolism after using NuvaRing to learn their treatment options and legal rights.

Due to the specialized nature of federal MDL drug injury cases, DrugRisk only recommends lawyers and law firms who have already handled NuvaRing lawsuits.

For more information on the research, side effects and litigation news related to NuvaRing and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*http://www.businessweek.com/ap/2012-11-29/merck-withdraws-eu-cancer-drug-application
**http://www.jpml.uscourts.gov/sites/jpml/files/JPML_Statistical_Analysis_of_Multidistrict_Litigation-2012.pdf
***Order # 1423, Novenber 20, 2012, Case: 4:08-md-01964-RWS


Contact